• Je něco špatně v tomto záznamu ?

Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate

J. Navrátilová, M. Karasová, M. Kohutková Lánová, L. Jiráková, Z. Budková, J. Pacherník, J. Šmarda, P. Beneš,

. 2017 ; 21 (9) : 1859-1869. [pub] 20170228

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025143

Neuroblastoma is the most common extracranial solid tumour of infancy. Pathological activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients. Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclinical trials as potential anti-cancer drugs. However, metabolic plasticity of cancer cells might undermine efficacy of this approach. In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase. It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells. The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids. Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate production in neuroblastoma cells, but not in normal fibroblasts and neuronal cells. Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells. Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities. The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025143
003      
CZ-PrNML
005      
20180716114648.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcmm.13106 $2 doi
035    __
$a (PubMed)28244639
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Navrátilová, Jarmila $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Center for Biological and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
245    10
$a Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate / $c J. Navrátilová, M. Karasová, M. Kohutková Lánová, L. Jiráková, Z. Budková, J. Pacherník, J. Šmarda, P. Beneš,
520    9_
$a Neuroblastoma is the most common extracranial solid tumour of infancy. Pathological activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients. Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclinical trials as potential anti-cancer drugs. However, metabolic plasticity of cancer cells might undermine efficacy of this approach. In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase. It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells. The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids. Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate production in neuroblastoma cells, but not in normal fibroblasts and neuronal cells. Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells. Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities. The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.
650    _2
$a adenosintrifosfát $x metabolismus $7 D000255
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a buněčné dýchání $x účinky léků $7 D019069
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a fibroblasty $x účinky léků $x metabolismus $7 D005347
650    _2
$a glukosa $x metabolismus $7 D005947
650    _2
$a lidé $7 D006801
650    _2
$a kyselina mléčná $x biosyntéza $7 D019344
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a mitochondrie $x účinky léků $x metabolismus $7 D008928
650    _2
$a molybden $x farmakologie $7 D008982
650    _2
$a neuroblastom $x enzymologie $x metabolismus $x patologie $7 D009447
650    _2
$a neurony $x účinky léků $x metabolismus $7 D009474
650    _2
$a oxidativní fosforylace $x účinky léků $7 D010085
650    _2
$a spotřeba kyslíku $x účinky léků $7 D010101
650    _2
$a fosforylace $x účinky léků $7 D010766
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a protoonkogenní proteiny c-akt $x antagonisté a inhibitory $x metabolismus $7 D051057
655    _2
$a časopisecké články $7 D016428
700    1_
$a Karasová, Martina $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Kohutková Lánová, Martina $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Jiráková, Ludmila $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Budková, Zuzana $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Pacherník, Jiří $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Šmarda, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Beneš, Petr $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Center for Biological and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
773    0_
$w MED00006785 $t Journal of cellular and molecular medicine $x 1582-4934 $g Roč. 21, č. 9 (2017), s. 1859-1869
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28244639 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180716114947 $b ABA008
999    __
$a ok $b bmc $g 1317274 $s 1022064
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 21 $c 9 $d 1859-1869 $e 20170228 $i 1582-4934 $m Journal of cellular and molecular medicine $n J Cell Mol Med $x MED00006785
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...